There are currently 42 active clinical trials seeking participants for Parkinson's Disease research studies. The states with the highest number of trials for Autism participants are Florida, California, New York and Texas.
Combining Aerobic Exercise and Virtual Reality for Cognitive-motor Rehabilitation in PD
NCT05385497
Recruiting
This project will provide preliminary data on the feasibility and effects of exercise and VR on motor behavior and neuroplasticity in PD. Results from this work will provide insight into whether combination interventions utilizing AE and VR have parallel effects on cognition, gait, and neuroplasticity in PD.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/10/2024
Locations: UT Health San Antonio- Dept. of Physical Therapy, San Antonio, Texas
Conditions: Parkinson's Disease
Register for Updates
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
NCT02071134
Recruiting
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/08/2024
Locations: Neurology and Pain Specialty, Aliso Viejo, California +78 locations
Conditions: Parkinson's Disease
Register for Updates
Gait Analysis in Neurological Disease
NCT02994719
Recruiting
The purpose of this study is to investigate whether speed-dependent measures of gait can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/02/2024
Locations: Clinical Research Center BIDMC, Boston, Massachusetts
Conditions: Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease, Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Gait, Frontal, Huntington Disease
Register for Updates
Clinical Laboratory Evaluation of Chronic Autonomic Failure
NCT03648905
Recruiting
Background: The autonomic nervous system controls automatic body functions. Researchers want to improve the tests used to diagnose autonomic failure. Orthostatic hypertension is a drop in blood pressure when a person stands up. Researchers want to focus on this sign of autonomic failure. Objective: To improve testing for conditions that cause autonomic nervous system failure. Eligibility: People ages 18 and older in one of these categories: Their blood pressure drops when they get up. They... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
03/29/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
Register for Updates
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
NCT05819359
Recruiting
The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical meaningful motor progression over 78 weeks in subjects with Parkinson's disease who have a pathogenic variant in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
03/28/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +95 locations
Conditions: Parkinson's Disease
Register for Updates
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
NCT05523570
Recruiting
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
Gender:
All
Ages:
Between 18 years and 45 years
Trial Updated:
03/19/2024
Locations: Frontage Clinical Services, Inc., Secaucus, New Jersey
Conditions: Parkinson's Disease
Register for Updates
PET Imaging Evaluation of [11C]SY08
NCT06098612
Recruiting
The overall goal of the proposed research is to evaluate the use of [11C]SY08 as a PET radiotracer for aggregated alpha synuclein (αS) in individuals with Parkinson's disease (PD), Multiple system atrophy (MSA), Dementia with Lewy Bodies (DLB) and healthy controls. The purpose of this study is to evaluate the use of [11C]SY08 as a PET radiotracer for αS fibrils in individuals with PD, MSA, DLB and healthy controls. The specific aims of the current study are: To determine brain uptake, distribu... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
03/11/2024
Locations: MGH, Charlestown, Massachusetts
Conditions: Parkinson's Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Healthy Controls
Register for Updates
Patterned Multichannel Vibrotactile Stimulation for the Longitudinal Treatment of Moderate Stage Parkinson's Disease
NCT05830110
Recruiting
The purpose of the present research is to examine the effectiveness of a non-invasive, vibrotactile stimulation protocol, known as coordinated reset (CR), for the alleviation of motor symptoms in patients with Parkinson's disease (PD). PD patients exhibit rigidity, slowness (bradykinesia) and poverty (akinesia) of movement as well as other symptoms. Treatment for PD is either pharmacological (first line) or invasive deep brain stimulation. The non-invasive, vibrotactile stimulation approach uses... Read More
Gender:
All
Ages:
Between 45 years and 90 years
Trial Updated:
02/20/2024
Locations: Synergic Medical Technologies, Eugene, Oregon
Conditions: Parkinson's Disease
Register for Updates
Ketamine for the Treatment of Depression in Parkinson's Disease
NCT04944017
Recruiting
The main purpose of this study is to examine the efficacy and safety of a repeated dosing ketamine infusion paradigm compared to placebo in individuals with PD. A subset of participants in each arm will undergo baseline and post-treatment PET and fMRI scans, to examine whether changes in synaptic density and reorganization of functional networks underlie ketamine's putative antidepressant effects in PD.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
02/14/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Parkinson's Disease, Depression
Register for Updates
Combined STN and NBM Deep Brain Stimulation for Mild Cognitive Impairment in Parkinson's Disease
NCT05968703
Recruiting
The goal of this clinical trial is to evaluate the safety and tolerability of a novel deep brain stimulation (DBS) of the Subthalamic Nucleus (STN) and Nucleus Basalis of Meynert (NBM) to treat cognitive and cognitive-motor symptoms in individuals with Parkinson's disease. The main question it aims to answer is: Is a combined deep brain stimulation approach targeting the STN and NBM with four DBS leads safe and tolerable for cognitive and cognitive-motor symptoms in individuals with Parkinson's... Read More
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
02/08/2024
Locations: Stanford Neuroscience Health Center, Stanford, California
Conditions: Parkinson's Disease, Mild Cognitive Impairment
Register for Updates
Natural History Protocol for Movement Disorders
NCT05413291
Recruiting
Background: A movement disorder is a condition that causes a person s body to move in ways that are not normal. There are different types. Some disorders cause movements people can t control, such as tics or shaking. Some cause reduced or slow movements. Movement disorders can cause disability in people. Sometimes members of the same family will have the same disorder. Researchers want to learn more about how people develop these disorders. This research could lead to better treatments. Object... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
02/08/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Movement Disorder, Tremor, Parkinson's Disease
Register for Updates
Retinal Imaging in Neurodegenerative Disease
NCT03233646
Recruiting
This study aims to develop and evaluate biomarkers using non-invasive optical coherence tomography (OCT) and OCT angiography (OCTA) as well as ultra-widefield (UWF) fundus photography to assess the structure and function of the retinal and choroidal microvasculature and structure in persons with mild cognitive impairment (MCI) and Alzheimer's Disease (AD), Parkinson's Disease (PD), or other neurodegenerative disease, diseases as outlined.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Mild Cognitive Impairment, Multiple Sclerosis, Huntington Disease, Neuro-Degenerative Disease, Alzheimer's Disease, Parkinson's Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Normal Cognition
Register for Updates